Takeda Pharmaceutical Co. (TAK)
(Delayed Data from NYSE)
$13.10 USD
+0.09 (0.69%)
Updated Dec 20, 2024 04:00 PM ET
After-Market: $13.10 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth F Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TAK 13.10 +0.09(0.69%)
Will TAK be a Portfolio Killer in December?
Zacks Investment Research is releasing its prediction for TAK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TAK
ADMA Stock Falls 19% From Its 52-Week High: Should You Buy the Dip?
Should ADMA Biologics Stock Be in Your Portfolio Pre-Q3 Earnings?
TAK: What are Zacks experts saying now?
Zacks Private Portfolio Services
ADMA Biologics Stock Skyrockets 262.1% YTD: How to Play the Stock?
TAK or CTLT: Which Is the Better Value Stock Right Now?
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
Other News for TAK
TD Cowen Reaffirms Their Buy Rating on Takeda Pharmaceutical Company (TAK)
Keros Therapeutics: Trading At Essentially Cash Value, Target Of $23 Per Share
Takeda Announces Subsidiary Liquidation and Merger Completion
Takeda's (TAK) Mezagitamab Gains New Clinical Trial Approval in China
Keros Therapeutics: How To Respond To Today's Major Safety Setback And Selloff